GSK Denmark
Presence
GSK is one of the...
- Forbes Global 2000 (#183);
- Fortune 500 Europe (#81);
- FTSE 350;
- Global Fortune 500 (#343);
- Stoxx 600.
GSK is a company listed under the stock ticker GSK (GB).
GSK has a direct presence in 21 countries.GSK has 23 subsidiaries including Aiolos Bio, GSK ANZ and GSK APAC.
They are in:
Acquisition, funding and merger involving GSK.
- GSK has announced the acquisition of Aiolos Bio (posted on January 12 2024).
- GSK has announced the acquisition of Bellus Health (posted on April 19 2023).
Executives
View the org chart displaying its 4 main executives
Most searched biographies at GSK Denmark
- Dominika Wiktor-Brown, General Manager
- Hemal Malde, Finance Director
- Thy Trock Andresen, Medical Director
Popular executive movements at GSK
- Jeannie Lee will join the company as Non-Executive Director on Mar. 4, 2024 (posted on February 29 2024).
Create your alert
to follow the executive moves at GSK Denmark.
Pharmaceuticals
GSK has 1,840 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Sanofi (France).
Popular M&A news in Pharmaceuticals
- ANI Pharmaceuticals has announced the acquisition of Alimera Sciences (posted on June 26 2024).
- Sun Pharma has acquired Taro Pharmaceutical (posted on June 25 2024).
- ONO Pharmaceutical has acquired Deciphera Pharmaceuticals (posted on June 12 2024).
Popular contacts in Pharmaceuticals
News
Press releases by GSK Denmark
- US FDA accepts for priority review GSK’s application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer | GSK
- GSK makes a strong start to 2024 with improving outlook for the year | GSK
- New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade | GSK
- GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA | GSK
- EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments | GSK
- Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer | GSK
- GSK completes acquisition of Aiolos Bio | GSK
- GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B | GSK
- DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma | GSK
- GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration | GSK
- View more press releases Close
Social media about GSK Denmark
- GSK Denmark on Wikipedia, Google News & Yahoo Finance
- GSK Denmark on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Janet Lee 
